Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 26, Issue 17, Pages 2895-2900Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2007.15.8428
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA127574-01A2, CA107040, CA1539632, K23 CA093657, CA93657, K23 CA107040, R01 CA127574, K23 CA107040-04] Funding Source: Medline
Ask authors/readers for more resources
Multiple myeloma is characterized by the clonal expansion of neoplastic plasma cells within the bone marrow, elevated serum immunoglobulin, and osteolytic bone disease. The disease is highly responsive to a wide variety of anticancer treatments including conventional cytotoxic chemotherapy, corticosteroids, radiation therapy, and a growing number of agents with novel mechanisms of action. However, few if any patients are cured with these modalities and relapse remains a critical issue. A better understanding of clonogenic multiple myleoma cells is essential to ultimately improving long-term outcomes, but the nature of the cells responsible for myeloma regrowth and disease relapse is unclear. We review evidence that functional heterogeneity exists in multiple myeloma and discuss potential strategies and clinical implications of the stem-cell model of cancer in this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available